Drugs / clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel
clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05582434 | Feb 2024 → Jun 2025 overdue | acne | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05582434 ↗ |
| Route | Topical | “Single topical treatment to be applied daily to area affected once daily.” NCT05582434 ↗ |